在一种新型体内模型中对强效抗乙肝病毒药物（-）顺式-5-氟-1-[2-（羟甲基）-1,3-氧硫杂环戊烷-5-基]胞嘧啶的评估。
Evaluation of the potent anti-hepatitis B virus agent (-) cis-5-fluoro-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl]cytosine in a novel in vivo model.
作者信息
Condreay L D, Jansen R W, Powdrill T F, Johnson L C, Selleseth D W, Paff M T, Daluge S M, Painter G R, Furman P A, Ellis M N
机构信息
Division of Experimental Therapy, Wellcome Research Laboratories, Research Triangle Park, North Carolina 27709.
出版信息
Antimicrob Agents Chemother. 1994 Mar;38(3):616-9. doi: 10.1128/AAC.38.3.616.
A murine model was developed to investigate the in vivo activity of anti-hepatitis B virus (HBV) agents. Mice with subcutaneous tumors of HBV-producing 2.2.15 cells showed reductions in levels of HBV in serum and in intracellular levels of HBV when the mice were orally dosed with (-) cis-5-fluoro-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl]cytosine (FTC). No effects on tumor size or alpha-fetoprotein levels were observed. FTC can selectively inhibit HBV replication at nontoxic doses.
建立了一种小鼠模型，以研究抗乙型肝炎病毒（HBV）药物的体内活性。当给产生HBV的2.2.15细胞皮下接种肿瘤的小鼠口服（-）顺式-5-氟-1-[2-（羟甲基）-1,3-氧硫杂环戊烷-5-基]胞嘧啶（FTC）时，小鼠血清中的HBV水平和细胞内的HBV水平均降低。未观察到对肿瘤大小或甲胎蛋白水平的影响。FTC可以在无毒剂量下选择性抑制HBV复制。
Zotero 插件